null

null

null

null

null

null

null

null

null

null

null

null

null

null

Near-zero debt; Lantern Pharma is effectively debt-free, relying on equity financing. A 200bps rate rise has negligible direct interest cost impact.

Minimal direct sensitivity; no material floating-rate debt. Higher rates increase equity dilution cost and lengthen runway burn, indirectly pressuring cash conservation.

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

Lantern is an AI/data-driven drug development company; primary dependencies are CRO partners and genomic data providers, not physical supply chains. Geopolitical chokepoints are largely not applicable.

Revenue is minimal and U.S.-centric; no material international revenue markets, so sovereign currency devaluation exposure is effectively zero.

Operations concentrated in Dallas, TX (USA); no significant international revenue-generating presence. Currency devaluation exposure is negligible.

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

RADR AI platform is proprietary; however, genomic data sourcing from partners (e.g., academic institutions, databases) could represent non-substitutable input dependency exceeding 30% of operational inputs.

AI-driven precision oncology drug development platform; cloud disruption would impair RADR platform operations materially within 30 days, requiring emergency migration.

Secondary model involves licensing RADR insights to pharma partners; cloud termination would freeze data analytics delivery, breaching partner obligations.

Moderate API coupling risk; RADR platform integrates genomic databases and cloud ML services. Switching costs are meaningful but not insurmountable given proprietary data ownership.

Low Howey risk; revenue model is B2B licensing and grant-funded drug development, not investment contracts. Primary revenue does not resemble a security offering.

Very High

Moderate GDPR/CCPA exposure; processes de-identified genomic/clinical data. Compliance frameworks needed but no known material violations. Patient data anonymization reduces peak exposure.

Low antitrust risk; niche AI oncology platform with limited market share. No dominant position in any defined market warranting regulatory scrutiny.

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

Predominantly transactional/milestone-based licensing and grants; recurring revenue fraction is low (~10-20%). Revenue is largely deal-dependent and non-subscription.

Monetizes via pharma licensing agreements, RADR platform access fees, and government/NIH grants. Milestone payments upon clinical development achievements are primary vectors.

Pricing tied to licensing deals and milestone gates; lacks scalable subscription pricing. Stress scenario: pharma budget cuts could delay or cancel milestone payments, impairing cash flow.

Moderate; RADR's proprietary AI and genomic data create differentiation, but small company size limits negotiating leverage against large pharma counterparties.

Software/IP licensing margins estimated 60-75%; offset by ongoing R&D spend. Net margins deeply negative due to pipeline investment. Gross margin bracket ~60-70%.

Low free-rider risk; RADR platform access is gated by licensing agreements. No open-access model. Partner churn risk exists if clinical programs fail or pharma reprioritizes.

Revenue growth is sublinear to headcount; AI platform scales without proportional hiring. Doubling revenue would require modest headcount increase (~20-30%), not doubling.

Marginal cost of growth is low once RADR platform is built; incremental licensing deals add revenue with minimal additional cost, suggesting improving unit economics at scale.

null

At 10x scale, CAC likely falls as RADR reputation grows; LTV/CAC improves given high licensing deal values (~$1M-$50M range) vs. modest BD costs. Unit economics favorable at scale.

Weak direct network effects; RADR improves with more genomic data ingestion (data flywheel), creating indirect/data network effect. Not a traditional platform network effect.

AI displacement risk is paradoxical; Lantern IS the AI disruptor. Larger AI-enabled pharma players could replicate RADR capabilities, posing competitive displacement risk.

Moderate resilience; oncology drug development is necessity-driven, but pharma licensing budgets can be cut in severe recessions. Grant funding provides partial buffer.

Pharmaceutical and biotechnology companies seeking AI-guided oncology drug development and patient stratification. High customer concentration risk given small deal volume.

Government/NIH grant programs funding precision medicine and oncology AI research. Concentration risk: loss of a single large grant materially impacts revenue.

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

Capital is being allocated toward future-state infrastructure (RADR platform development, clinical pipeline advancement). No legacy operations to cannibalize. CapEx is R&D-intensive, forward-looking.

0001763950

LTRN